18 results about "Lactobacillus jensenii" patented technology

The present disclosure relates to a composition comprising Lactobacillus crispatus, Lactobacillus rhamnosus, Lactobacillus jensenii, Lactobacillus gasseri and 2'-fucosyllactose for use as a supplement to support healthy vaginal microbiota in pregnant women.

This invention proposes a molecular marker for *Lactobacillus japonicus*, which was deposited on February 7, 2023, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 26505. The molecular marker comprises a nucleotide sequence selected from one of the following: (1) the nucleotide sequence shown in SEQ ID NO: 24; (2) a nucleotide sequence having at least 97%, 98%, 99%, or higher homology to the nucleotide sequence shown in SEQ ID NO: 24; or (3) a nucleotide sequence having one or more nucleotide substitutions, deletions, or insertions in the nucleotide sequence shown in SEQ ID NO: 24. Using the molecular marker of this invention, not only can the target *Lactobacillus japonicus* be screened quickly and easily, but it can also highly specifically identify the target *Lactobacillus japonicus*, eliminating interference from other strains.

A hypotonic or iso-osmolal vaginal probiotic gel-forming formulation comprising: (a) vaginal microbiota, (b) a gel-forming polymer at a concentration at or below the critical gel concentration of the polymer under isotonic conditions and a temperature between room temperature and body temperature (25 to 37°C), and (c) a hypotonic carrier to form a hypotonic formulation of the polymer, wherein the vaginal microbiota is selected from the group consisting of Lactobacillus crispatus, Lactobacillus iners, Lactobacillus gasseri, or Lactobacillus jensenii. Said formulation for use in the treatment of bacterial vaginosis or a sexually transmitted disease.

The present invention relates to a synergistic bioactive composition for women's health, and more particularly to compositions comprising Lactobacilli and Lactoferrin for supporting vaginal health. The invention specifically provides a composition comprising Lactobacillus crispatus, Lactobacillus jensenii, Lactobacillus fermentum, and Lactoferrin, formulated with one or more pharmaceutically acceptable excipients. The invention further pertains to compositions and kits intended for promoting a balanced vaginal microbiota, maintaining healthy vaginal conditions, and supporting overall vaginal ecosystem stability.

The present invention provides compositions and methods for treating patients. [Solution] The exemplary composition may include a vaginal microbiome composition. The vaginal microbiome composition may include a mixture of bacteria. The bacterial mixture may include Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii, and Lactobacillus rhamnosus.

The present invention relates to vaginal pharmaceutical compositions and methods and uses thereof, including: treating and preventing genital inflammation in a subject; modulating the level of one or more of Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus gardneri, Lactobacillus jensenii, and Lactobacillus iners in the genital microbiome of a subject; and maintaining or improving the integrity of the cervical-vaginal epithelial barrier in a subject.

The invention belongs to the technical field of compound microorganism compositions, and particularly relates to a female health conditioning composition based on Lactobacillus complex flora and a medicinal fungus extract, the composition comprises compound lactic acid bacteria composed of Lactobacillus crispatus, Lactobacillus jensenii and Lactobacillus reuteri according to a specific ratio, and the compound lactic acid bacteria comprise Lactobacillus crispatus, Lactobacillus jensenii and Lactobacillus reuteri according to a specific ratio. According to the invention, a prebiotic compound formed by galactooligosaccharide, fructo-oligosaccharide and inulin is matched, extracts of lucid ganoderma, hericium erinaceus, poria cocos, cordyceps sinensis and inonotus obliquus are combined, and cranberry extract powder and pineapple powder are supplemented. Lactic acid bacteria form a double-layer microcapsule through electrostatic spraying, the three functional components construct a three-layer composite structure through layered pressing, and finally microcapsule powder is formed. Through targeted regulation of vaginal microecology, inhibition of inflammatory response and repair of mucosal barrier, the composition has the characteristics of stable structure, synergistic components and remarkable conditioning effect, and is suitable for health management of female genital tracts.

Disclosed are novel Lactobacillus strains, relating to a new Lactobacillus crispatus V435 strain and a new Lactobacillus jensenii V216 strain, and a composition comprising the strains used in the prevention or treatment of vaginitis. The Lactobacillus crispatus V435 strain is capable of producing lactic acid at a high yield, and the Lactobacillus jensenii V216 strain is capable of producing lactic acid and hydrogen peroxide at a high yield. Both strains have an excellent ability to inhibit clinically isolated Gardnerella, clinically isolated Atopobium, and fungi, a good ability to inhibit mixed vaginal pathogenic flora, and can be stably colonized in vaginal environments to become a dominant flora therein. The two strains exhibit a mutually beneficial symbiotic relationship without generating an antagonistic effect, and also exhibit a synergistic effect, resulting in stronger probiotic capabilities than a single dominant strain.

The invention relates to the technical field of gene detection, in particular to a primer group and application thereof, and a training method of a bacterial vaginitis diagnosis model. The primer group is used for diagnosing bacterial vaginitis and comprises a specific primer, and the target areas are used for specifically amplifying the following target pathogens: Atortobacterium vaginalis, Gardneria vaginalis, type 1 giant coccus, type 2 giant coccus, bacterial vaginitis related bacteria 2, campylobacter kirschengensis, campylobacter pudicus, two-way prevotella, Lactobacillus crispatus, Lactobacillus inervis, Lactobacillus gasseri and Lactobacillus jensenii. The invention also provides application of the primer group and a training method of a bacterial vaginitis diagnosis model. The primer group can be used for carrying out high-throughput sequencing on a to-be-detected sample, 12 target pathogens can be detected at the same time, a bacterial vaginitis diagnosis model is further constructed, and the primer group can be used for clinical diagnosis of bacterial vaginitis and has good specificity and sensitivity.

The present disclosure provides use of a probiotic composition comprising active ingredients including Lactobacillus johnsonii, Lactobacillus gasseri, Lactobacillus crispatus, and Lactobacillus jensenii in the preparation of a microbial formulation, wherein the microbial formulation is used for: improving the therapeutic effect of an additional drug for treating bacterial vaginosis in the treatment of bacterial vaginosis; improving the prognosis of bacterial vaginosis treated with an additional drug for treating bacterial vaginosis; treating, preventing, mitigating, and / or controlling the recurrence of bacterial vaginosis in a subject; treating, preventing, mitigating, and / or controlling atrophic vaginitis in a subject; improving the Nugent score of a subject; or ameliorating vaginal dryness in a subject.

1. The name of the present design product: bottle sticker (snowy lactic acid bacteria). 2. The use of the present design product: label sticker used for the packaging of beverage products. 3. The design points of the present design product: in the combination of patterns and colors. 4. The picture or photo that best indicates the design points: front view. 5. The design for which protection is sought contains colors. 6. The present design product is a planar product, and the rear view, left view, right view, top view, and bottom view are omitted.

The invention relates to a flora prediction model for detecting premature delivery risk and a kit and application thereof. Through early-stage mNGS data collection and analysis, premature related strains are obtained, and through a large number of experimental screening and optimization, a set of optimal primer probe group is finally determined. The invention relates to a premature delivery risk calculation method, which comprises the following steps of: selecting 12 floras, namely lactobacillus crispatus, lactobacillus gasseri, lactobacillus inertus, lactobacillus jensenii, escherichia coli, enterococcus faecalis, enterobacter aerogenes, group B hemolytic streptococcus, ureaplasma parvum, chlamydia trachomatis, diplococcus gonorrhoeae and gardnerella vaginalis, and establishing a fluorescent quantitative PCR (Polymerase Chain Reaction) method and a premature delivery risk calculation model aiming at the detection of the 12 floras. Compared with an existing detection method, the method is simple, convenient, rapid, high in sensitivity and high in specificity, the false positive and false negative risk is reduced, and the purpose of batch detection is achieved. Clinically, the change of microbial flora in the reproductive system of a pregnant woman can be rapidly detected, corresponding treatment measures are taken, the risk of PTB occurrence is reduced, and the kit has a good application prospect.

The invention discloses a traditional Chinese medicine compound for treating sarcopenia and preparation and application of fermentation liquor of the traditional Chinese medicine compound, and belongs to the field of traditional Chinese medicine application. The traditional Chinese medicine compound for treating sarcopenia is prepared from the following raw materials in parts by weight: 10 to 30 parts of radix astragali seu hedysari, 5 to 25 parts of radix codonopsis, 5 to 25 parts of herba cistanche, 5 to 25 parts of folium cortex eucommiae, 5 to 25 parts of rhizoma polygonati, 5 to 25 parts of radix angelicae sinensis, 5 to 25 parts of fructus crataegi and 5 to 25 parts of roasted fructus hordei germinatus. The traditional Chinese medicine compound fermentation liquor for treating sarcopenia is prepared by the following steps: uniformly mixing the traditional Chinese medicines in parts by weight, adding water, decocting to obtain decoction, and concentrating the decoction to obtain concentrated liquor; inoculating lactobacillus johnsonii, lactobacillus fermentum and bifidobacterium adolescentis into the concentrated solution, and fermenting to obtain fermentation liquor; the traditional Chinese medicine composition has the advantages that the pathological state of sarcopenia is improved through the traditional Chinese medicine composition, and meanwhile a new scheme is provided for the probiotic fermented traditional Chinese medicine decoction.

The invention discloses a novel lactobacillus strain, and relates to novel lactobacillus crispatus V435, lactobacillus jensenii V216 and a composition for preventing or treating vaginitis containing the strain. Wherein the lactobacillus crispatus V435 can produce lactic acid at high yield; lactobacillus jensenii V216 can produce lactic acid and hydrogen peroxide at high yield. The two strains have excellent capability of inhibiting clinically-isolated gardnerella, clinically-isolated Atortobacteria and fungi, have relatively good inhibition capability on mixed vaginal pathogenic bacteria groups, and can be stably planted in a vaginal environment to become a dominant bacterial group in the vaginal environment. The two strains are mutualistic, do not generate antagonism, have a synergistic effect, and generate a probiotic ability stronger than that of a single dominant strain.

The application provides a probiotic crystal ball preparation containing lactobacillus jensenii and bifidobacterium longum, which comprises a shell structure and a core structure, wherein the shell structure comprises gelatin, glycerol and water; and the core structure comprises lactobacillus jensenii, bifidobacterium longum and hydrogenated oil. The lactobacillus jensenii has a preservation number of CCTCC NO: M2022172; and the bifidobacterium longum has a preservation number of CCTCC NO: M2019780. The application adopts a double-layer seamless capsule technology with gelatin as the shell material, hydrogenated oil and bacterial powder as the core, so that the probiotics can not be digested by gastric juice and have a high survival rate in the intestinal tract. Moreover, the core of the application uses the screened lactobacillus jensenii VHProbi A17 strain which does not produce hemolysin and cannot dissolve blood cells, and has safety. The lactobacillus jensenii has scavenging effects on DPPH free radicals and hydroxyl radicals, and has a wide antibacterial spectrum.

The present application belongs to the technical field of composite microbial composition, and particularly relates to a female health conditioning composition based on Lactobacillus composite flora and medicinal fungus extract, which comprises composite lactic acid bacteria composed of Lactobacillus crispatus, Lactobacillus jensenii and Lactobacillus reuteri in a specific ratio, a prebiotic composite formed by galactooligosaccharide, fructooligosaccharide and inulin, extracts of Ganoderma lucidum, Hericium erinaceus, Poria cocos, Cordyceps sinensis and white birch fungus, and cranberry extract powder and pineapple powder. The lactic acid bacteria is formed into double-layer microcapsules by electrostatic spraying, and three types of functional components are constructed into a three-layer composite structure by layering and pressing, so as to finally form microcapsule powder. The present application has the characteristics of stable structure, synergistic components and remarkable conditioning effect by targeting regulating vaginal microecology, inhibiting inflammatory response and repairing mucosal barrier, and is suitable for female reproductive tract health management.

The application discloses a primer probe combination, a kit and application for detecting pathogenic microorganisms in a genital tract, wherein the primer probe combination comprises primer probe sequences shown in SEQ ID NO. 1-SEQ ID NO. 96, the pathogenic microorganisms in the genital tract include 27 pathogenic microorganisms which can cause diseases in the genital tract, such as Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma hominis, Mycoplasma genitalium, Candida albicans, Candida glabrata, Candida tropicalis, Candida auris, Candida krusei, Candida dubliniensis and the like, and four common vaginal lactobacilli, such as Lactobacillus crispatus, Lactobacillus jensenii, Lactobacillus gasseri and Lactobacillus iners, and further include a human internal standard. Based on the fluorescence quantitative PCR technology, the 27 pathogenic microorganisms which can cause diseases in the genital tract and the four common vaginal lactobacilli can be simultaneously detected in an in-vitro sample, the main pathogenic microorganisms of the genital tract infection can be covered, the evaluation of the vaginal ecological environment can be satisfied, the detection time is shortened to about 40 minutes, and the specificity and the sensitivity are good.

Compositions and methods for treating patients are disclosed. An example composition may include a vaginal microbiota composition. The vaginal microbiota composition may include a mixture of bacteria. The mixture of bacteria may include Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii / Lactobacillus mulieris and Lactobacillus rhamnosus.